The study investigating combinational therapeutic efficacy via in vitro and in vivo breast cancer models revealed that CUR effectively sensitized DOXO-resistant cancer cells to apoptosis through suppression of the NF-κB pathway. Here, NFKB1 is linked to breast carcinoma.